[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adrenalectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adrenalectomy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,74,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100629125","radiofrequency-ablation-versus-adrenalectomy-for-adenoma-in-patients-with-primary-aldosteronism-and-hypertension-100629125",false,"NCT07470580","Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension","Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension: a Multicentre Prospective Randomized Study","ADERADHTA2","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Hypertension confirmed into the previous 9 months by ABPM 24h SBP\u002FDBP \\>130 and\u002For\u002F80 mmHg and\u002For diurnal SBP\u002FDBP \\> 135 and\u002For 85 mmHg and\u002For nocturnal SBP\u002FDBP \\>120 and\u002For 70 mmHg with or without antihypertensive treatment\n* Diagnosis of primary aldosteronism confirmed by hormonal assays no more than 1 year before inclusion\n* Presence of a unilateral adrenal nodule \\\u003C4 cm considered suggestive of a Conn's adenoma on an prior adrenal CT or MRI scan, no more than 1 year before inclusion\n* Adrenal venous sampling if age \\> 35 years (and according to investigator decision if age \\\u003C35 years) to look for a lateralization of secretion: cannulation was successful when adrenal\u002Fperipheral venous cortisol gradients\\>2 and lateralization was assessed by comparison of right and left adrenal venous aldosterone\u002Fcortisol ratios with a cut off value\\>4 ipsilateral to the nod side to define a positive lateralization of secretion (2) no more than 1 year before inclusion\n* nodule accessible to RFA according to the judgement of the interventional radiologist performing radiofrequency before randomisation\n* nodule accessible to surgery\n* patient willing to return for 6-month follow-up\n* adult patient able to read the information sheet and give consent to take part in the study\n* Patients affiliated to the French Health Insurance\n\nExclusion Criteria:\n\n* a negative lateralization of secretion on adrenal venous sampling\n* presence of bilateral adrenal tumours\n* contralateral or bilateral macronodular adrenal hyperplasia\n* no documented primary aldosteronism\n* Cushing's syndrome or pheochromocytoma\n* adrenal tumour \\> 4 cm\n* refusal to perform adrenal catheterisation if age \\> 35 years\n* double anti-platelet aggregation, coagulation disorders or patients treated with anticoagulant treatment that cannot be stopped\n* contraindication to anaesthesia\n* excessive proximity to sensitive adjacent organs\n* patient who has had a heart attack or stroke within the last 6 months\n* allergy to iodine\n* renal insufficiency defined as a clearance of \\\u003C30 ml\u002Fmin\n* refusal to undergo radiofrequency ablation or adrenal surgery\n* minors and patients under guardianship, curatorship or safeguard of justice\n* Inability to speak, read or write French fluently\n* patients who refuse follow-up\n* pregnant women or women wishing to become pregnant in the short term; breast-feeding\n* person taking part or having taken part in other interventional research in the previous 6 months\n* any other relevant exclusion criteria as determined by the investigator","ALL","18 Years",{"count":20,"type":21},134,"ESTIMATED","INTERVENTIONAL",[24],"NA","Primary aldosteronism (PA) is characterized by hypertension, frequent hypokalaemia, and an inappropriately high aldosterone-to-renin ratio (ARR). Aldosterone-producing adenoma (APA or Conn syndrome) is one of the main causes of primary aldosteronism. Laparoscopic (LA) total-adrenalectomy or adenoma selective is an option to normalize or at least improve blood pressure (BP) control, hypokalaemia, and normalize the ARR. However, the reported result of surgery is around 50% of clinical cure rate with an overall complication rate of 5 to 14% whereas hormonal success reached around 95%.\n\nMore recently, radiofrequency ablation (RFA) has been used for patients with primary aldosteronism and unilateral adenoma.\n\nInvestigator Team assume that treatment of unilateral PA by RFA could achieve similar efficacy to treatment by LA, with potentially less adverse events, and could be a more cost-efficient procedure.",[27,28,29],"Primary Aldosteronism Due to Conn Adenoma","Radiofrequency Ablation Treatment","Adrenalectomy",[31,32,33,34,35,36,37,38],"Primary aldosteronism","hypertension","hypokalaemia","aldosterone-to-renin ratio","Aldosterone-producing adenoma","Conn syndrome","radiofrequency ablation","adrenalectomy","RECRUITING","2026-06-10",{"date":42,"type":43},"2026-06-11","ACTUAL",{"date":45,"type":43},"2026-06-05",{"date":47,"type":21},"2030-06-01",{"name":49,"class":50},"University Hospital, Toulouse","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":51},"100547365","laparoscopic-versus-robotic-lateral-transabdominal-adrenalectomy-100547365","NCT06407024","Laparoscopic Versus Robotic Lateral Transabdominal Adrenalectomy","Laparoscopic Versus Robotic Lateral Transabdominal Adrenalectomy: a Single-center Randomized Prospective Trial","Inclusion Criteria:\n\n1. Men and women between ages 18 and 75\n2. Diagnosis of an adrenal tumor\u002Fpathology planned for a minimally invasive adrenalectomy at the department of endocrine surgery at the Cleveland Clinic.\n\nExclusion Criteria:\n\n1. Requirement for an open adrenalectomy based on imaging studies suggesting an aggressive cancer.\n2. The presence of extensive surgical history precluding a minimally invasive approach to be undertaken.\n3. Patients planned for a partial, rather than a complete adrenalectomy, as the former is a much easier procedure.\n4. Patients planned for a posterior adrenalectomy (these would be patients with an extensive surgical history with significant intra-abdominal adhesions and those requiring bilateral adrenalectomy).\n5. Mental incapacity or language barrier\n6. Any condition, unwillingness, or inability, not covered by any of the other exclusion criteria, which, in the study clinician's opinion, might jeopardize the subject's safety or compliance with the protocol","75 Years",{"count":61,"type":21},54,[24],"This study is being done to compare Laparoscopic vs Robotic lateral transabdominal adrenalectomy, these procedures are both standard of care.\n\nThe study team would like to compare both patient outcomes and surgeon efficiency and perspectives among both procedures.\n\nThe information from this study will help improve patient care, patient outcomes and maximize the appropriate utilization of resources in adrenal surgery.",[29],"2026-01-29",{"date":67,"type":43},"2026-02-02",{"date":69,"type":43},"2024-05-22",{"date":71,"type":21},"2026-12-31",{"name":73,"class":50},"The Cleveland Clinic",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100612338","china-adrenal-venous-sampling-investigation-100612338","NCT07252284","CHina Adrenal Venous saMPling InvestigatiON","China Adrenal Venous Sampling Investigation: A National Multicenter Study","CHAMPION","Inclusion Criteria:\n\n1. Patients with confirmed primary aldosteronism;\n2. Patients undergoing adrenal venous sampling for subtype classification of primary aldosteronism.\n\nExclusion Criteria:\n\n1. Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months；\n2. An estimated glomerular filtration rate \\\u003C45 ml\u002Fmin\u002F1.73 m2, or serum creatinine \\>176 μmol\u002FL；\n3. Patients who refuse adrenalectomy;\n4. Suspected of having an adrenocortical carcinoma;\n5. Allergy to contrast agent;\n6. Pregnant, nursing, or planning to become pregnant",{"count":83,"type":21},5000,"5 Years","OBSERVATIONAL","Primary aldosteronism (PA) is a major cause of secondary hypertension, yet its optimal diagnosis and management remain challenging. This study comprehensively evaluates adrenal venous sampling (AVS), addressing key clinical, technical, and methodological issues, and aims to clarify the relationship between AVS-guided management and long-term clinical and biochemical outcomes to optimize patient care and prognosis.",[88,89,29],"Hyperaldosteronism","Adrenal Venous Sampling",[91,88,92,93,94],"Adrenal venous sampling","Antecubital approach","Femoral approach","Main adverse cardiovascular events","2025-11-19",{"date":97,"type":43},"2025-11-26",{"date":99,"type":43},"2025-05-01",{"date":101,"type":21},"2029-08-31",{"name":103,"class":50},"Chinese Academy of Medical Sciences, Fuwai Hospital",76,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":122,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100595038","petal-trial-impact-of-gallium-68-pentixafor-pet-ct-on-surgical-outcomes-in-primary-aldosteronism-100595038","NCT07027254","PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism","A Randomized Controlled Trial to Evaluate the Effect of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Patients With Primary Aldosteronism (The PETAL Trial)","Inclusion Criteria:\n\n* Age ≥19 years\n* Diagnosed with PA per 2016 Endocrine Society guidelines\n* Underwent adrenal CT\n* Signed informed consent\n\nExclusion Criteria:\n\n* Women who are pregnant, breastfeeding, or may become pregnant\n* Individuals who refuse to undergo surgery\n* Individuals for whom 68Ga-Pentixafor PET\u002FCT, 11C-Metomidate PET\u002FCT, or adrenal venous sampling (AVS) is not feasible or is refused due to underlying conditions\n* Individuals who refuse or experience adverse effects from dexamethasone premedication required for 11C-Metomidate PET\u002FCT\n* Individuals with a history of abdominal open surgery or retroperitoneal surgery on the same side as the planned adrenalectomy\n* Any individual deemed unsuitable for the study at the discretion of the investigator","19 Years",{"count":114,"type":21},90,[24],"This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET\u002FCT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET\u002FCT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.",[118,119,120,121,29],"Primary Aldosteronism","Secondary Hypertension","Aldosterone-Producing Adenoma","Idiopathic Hyperaldosteronism",[31,123,124,125,126,127,128,29],"Gallium-68 pentixafor","11C-metomidate","PET\u002FCT","adrenal venous sampling","PASO","PAMO","2025-06-16",{"date":131,"type":43},"2025-06-18",{"date":133,"type":21},"2025-06-25",{"date":135,"type":21},"2027-12-01",{"name":137,"class":50},"Seoul National University Hospital",2]